Description: Phase 1 First-in-Human Study of Leukocyte Immunoglobulin-Like Receptor B2 Inhibitor Monoclonal Antibody JTX-8064, as Monotherapy & in Combination with a Programmed Cell Death Receptor-1 Inhibitor, in Adult Subjects with Advanced Refractory Solid Tumor Malignancies
Mechanism of Action: JTX 8064 (mAB to LILRB2-myeloid checkpoint) with or without PD1 inhibitor
Target Patient Population: Expansion cohorts Head & Neck, Ovarian, Clear Cell RCC, and cutaneous squamous cell carcinomas..
Study Design: Drug is given IV every 3 weeks.